检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.
研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLC
A. Aguilar, M. Cobo, A. Azkarate,A. Calles, M. Gonzalez-Cao, A. Cantero, J. Terrasa,R. Alvarez,M. A. Molina, R. Rosell
JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S85-S86
引用0浏览0引用
0
0
199P Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
R. Rosell, J.L. Gómez-Vázquez, E. Jantus Lewintre, M. Ito,P. Cao, X. Cai, B. Xing, S. Calabuig Fariñas,A.F. Cardona, J.K. Rodríguez, M. Marco Jordán, C. Pedraz Valdunciel,
Journal of Thoracic Oncology（2023）
引用0浏览0引用
0
0
2325P Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
R. Rosell, A. Jain, J. Codony-Servat, C. Shivamallu, S.P. Kollur,A. Prasad, P. Vishwanath, E. Jantus Lewintre, M. Ito, A.F. Cardona Zorrilla, O.G. Arrieta Rodriguez, C. Pedraz-Valdunciel,
Annals of Oncology (2023): S1188-S1188
引用0浏览0引用
0
0
Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)
A. Aguilar,M. Gonzalez Cao, C. Mayo de las Casas, M. A. Molina, C. Aguado Esteban, J. Bosch Barrera, R. Rosell
JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S648-S648
引用0浏览0引用
0
0
The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
R. Rosell, A. Jain, J. Codony-Servat, C. Shivamallu, S. Prasad Kollur,A. Prasad, E. Jantus-Lewintre, M. Ito, A. F. Cardona, O. Arrieta, P. Cao, X. Cai,
JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S112-S112
引用0浏览0引用
0
0
178P Targeting XPO1-dependent nuclear export of HMGB1 in non-small cell lung cancer
M. Gonzalez-Cao, X. Cai, J.W.P. Bracht, X. Han, Y. Yang, C. Pedraz, M.T. Moran Bueno, J. García-Corbacho,A. Aguilar, R. Bernabe Caro, P.R. De Marchi, L. Sussuchi Da Silva,
Journal of Thoracic Oncology（2023）
引用0浏览0引用
0
0
79TiP Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLC
A. Aguilar, M. Cobo, A. Azkarate,A. Calles, M. Gonzalez-Cao, A. Cantero, J. Terrasa,R. Álvarez,M.Á. Molina, R. Rosell
Journal of Thoracic Oncologyno. 4 (2023): S85-S86
引用0浏览0引用
0
0
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
D Rodríguez-Abreu, M Cobo, S García-Román, S Viteri-Ramírez, N Jordana-Ariza, B García-Peláez,N Reguart,A Aguilar, J Codony-Servat, A Drozdowskyj,M A Molina-Vila,E d'Hondt,
Lung Cancer（2022）
引用3浏览0WOS引用
3
0
加载更多
作者统计
  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn